Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 3:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 3,756 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Phase duration Clear all

Conditions: Major Depressive Disorder
Interventions: ADT, OPC-34712; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,036 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 32
States / cities: Arcadia, California • San Diego, California • Sherman Oaks, California + 28 more

Conditions: Oral Cavity Squamous Cell Carcinoma
Interventions: NisinZ® P, Surgery (non-interventional, standard of care); Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Non-muscle Invasive Bladder Cancer (NMIBC)
Interventions: inodiftagene vixteplasmid; Drug
Lead sponsor: Anchiano Therapeutics Israel Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 48
States / cities: Anchorage, Alaska • Gilbert, Arizona • Phoenix, Arizona + 40 more

Conditions: Diabetes (DM), Diabetic Ketoacidosis, Ketosis Prone Diabetes, Hyperglycaemia (Diabetic)
Interventions: Arginine hydrochloride, Sodium Chloride 0.9%; Drug
Lead sponsor: David K Carroll; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Small Cell Lung Cancer, Small Cell Lung Cancer Extensive Stage
Interventions: Nivolumab, 177Lu-DOTA0-Tyr3-Octreotate; Drug · Radiation
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Hackensack, New Jersey

Conditions: Leukemia
Interventions: rituximab, fludarabine phosphate; Biological · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 379
States / cities: Anniston, Alabama • Huntsville, Alabama • Fort Smith, Arkansas + 247 more

Conditions: Carcinoma, Intraductal, Noninfiltrating
Interventions: Pembrolizumab, Intralesional mRNA 2752; Drug · Biological
Lead sponsor: Laura Esserman; Other
Eligibility: 18 Years and older · Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Multiple Myeloma
Interventions: BIW-8962; Drug
Lead sponsor: Kyowa Kirin Co., Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 5
States / cities: Tampa, Florida • Chicago, Illinois • Detroit, Michigan + 2 more

Conditions: Brain Tumor, Recurrent
Interventions: Photofrin (porfimer sodium) & photodynamic therapy.; Drug
Lead sponsor: Harry T Whelan, MD; Other
Eligibility: 6 Months to 18 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Wauwatosa, Wisconsin

Conditions: Squamous Cell Carcinoma of the Head and Neck
Interventions: Hemopurifier, Pembrolizumab 200mg IV; Device · Drug
Lead sponsor: Aethlon Medical Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Venezuelan Equine Encephalomyelitis
Interventions: 0.5 mL Inactivated, Dried, C-84, TSI-GSD 205, Lot 7, Run 1; Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Fort Deterick, Maryland

Conditions: Schizophrenia, Schizo Affective Disorder, Social Skills
Interventions: social VR (virtual reality) training, Cognitive training (control game); Behavioral
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Haemophilia A Without Inhibitors, Haemophilia B Without Inhibitors
Interventions: Concizumab; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 12
States / cities: Los Angeles, California • Orange, California • Augusta, Georgia + 9 more

Conditions: Chronic Kidney Disease, Type 1 Diabetes Mellitus
Interventions: Finerenone, Placebo; Drug · Other
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 28
States / cities: Surprise, Arizona • Stanford, California • Vallejo, California + 22 more

Conditions: Non Small Cell Lung Cancer
Interventions: Ramucirumab, Paclitaxel, Carboplatin; Biological · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 7
States / cities: Beverly Hills, California • San Francisco, California • Aurora, Colorado + 4 more

Conditions: Healthy Study Participants, Participants With Mild Asthma
Interventions: Alprazolam, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 2
States / cities: North Dartmouth, Massachusetts • Raleigh, North Carolina

Conditions: Hematologic Neoplasms
Interventions: SNX-5422; Drug
Lead sponsor: Esanex Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 4
States / cities: Augusta, Georgia • Chapel Hill, North Carolina • Pittsburgh, Pennsylvania + 1 more

Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia, Relapsed, Adult
Interventions: Decitabine, Bone marrow biopsy/aspirate, Peripheral blood draw, Skin biopsy, Buccal swab; Drug · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Advanced Cancer
Interventions: RDEA119; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 3
States / cities: Scottsdale, Arizona • Aurora, Colorado • Buffalo, New York

Conditions: Osseointegration Infection
Interventions: intraosseous antibiotic delivery; Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 5
States / cities: Aurora, Colorado • New York, New York • Charlotte, North Carolina + 2 more

Conditions: Idiopathic Parkinson's Disease
Interventions: Rotigotine, Placebo; Drug · Other
Lead sponsor: UCB BIOSCIENCES GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 25
States / cities: Birmingham, Alabama • Oxnard, California • Ormond Beach, Florida + 21 more

Conditions: Amyotrophic Lateral Sclerosis, Healthy Volunteer
Interventions: SAR443820, Erythromycin ethyl succinate, Itraconazole; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: TNBC, TNBC - Triple-Negative Breast Cancer, Early Stage Triple-Negative Breast Carcinoma
Interventions: Ivonescimab, Carboplatin, Docetaxel; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 4
States / cities: Los Angeles, California • Pasadena, California • Torrance, California

Conditions: Primary Mediastinal Large B-Cell Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Etoposide Phosphate, Filgrastim, Lumbar Puncture, Nivolumab, Pegfilgrastim, Positron Emission Tomography, Prednisolone, Prednisone, Radiation Therapy, Rituximab, Rituximab and Hyaluronidase Human, Vincristine Sulfate; Procedure · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years and older
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 215
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 162 more

Search by objective public record fields.

Study of Safety & Tolerability of OPC-34712 as Adjunctive Therapy in Treatment of Adult Patients With Major Depressive Disorder

Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC)

Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC

Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes

Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer

Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia

Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS)

Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma

Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors

Hemopurifier Plus Pembrolizumab in Head and Neck Cancer

Safety and Immunogenicity Study of Venezuelan Equine Encephalomyelitis (VEE) Vaccine as Booster Vaccine in Adults

Virtual Reality Training for Social Skills in Schizophrenia - Comparison With Cognitive Training

Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors

A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes

A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer

A Study to Assess the Pulmonary Safety of Staccato Alprazolam in Healthy Study Participants and in Study Participants With Mild Asthma

Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies

Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia

Phase 1 Dose-escalation PK/PD Trial in Advanced Cancer Patients

Intraosseous Antibiotics for Osseointegration

Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy

A Study to Assess the Effect of Erythromycin on the Test Medicine (SAR443820) When Given Orally as Tablets to Healthy Adult Male and Female Participants (Part A); and the Effect of Itraconazole on the Test Medicine (SAR443820) When Given Orally as Capsules to Healthy Adult Male Participants (Part B)

Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma